Potent Antifolates as New Therapeutics for MRSA

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,517,860.00
Award Year:
2010
Program:
STTR
Phase:
Phase II
Contract:
2R42AI065143-02A1
Agency Tracking Number:
R42AI065143
Solicitation Year:
2010
Solicitation Topic Code:
NIAID
Solicitation Number:
PHS2010-2
Small Business Information
UNIVERSITY OF CONNECTICUT STORRS
ALBERTON, MT, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
130194082
Principal Investigator:
DENNIS WRIGHT
(406) 864-0022
DENNIS.L.WRIGHT@MAIL.PROMILIAD.COM
Business Contact:
DANA WARREN
(860) 486-3622
osp@uconn.edu
Research Institution:
University Of Connecticut Storrs

438 Whitney Road Extension, Unit 1133
STORRS-MANSFIELD, CT, 06269-
() -
Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): This Phase II STTR proposal describes a collaborative effort between researchers in the Department of Pharmaceutical Sciences at the University of Connecticut and Promiliad Biopharma to develop efficacious antibiotics targeting both methicillin-resistant strains of Staphylococcus aureus (MRSA) and Streptococcus pyogenes. We have recently completed a Phase I STTR grant that was focused on developing agents against the parasitic protozoan Cryptosporidium hominis by targeting the essential enzyme dihydrofolate reductase (DHFR). Through this work we developed the most potent and selective inhibitors of this enzyme reported to date and showed efficacy against the cultured parasite. In parallel with these efforts targeting Cryptosporidium, we examined the generality of this compound class to inhibit DHFR from other pathogenic organisms and found that this scaffold can be customized to potently target a wide range of pathogenic DHFR enzymes, including that from MRSA and Streptococcus pyogenes. We intend to capitalize on the high-profile nature of these organisms by switching the focus of our first proof-of-concept antibiotic. We have shown that the compounds effectively inhibit the growth of various phenotypes of MRSA and Streptococcus pyogenes. Moreover, we have determined several high-resolution crystal structures of the pathogenic MRSA enzyme in complex with representative inhibitors, placing us in a strong position to further develop these new antibiotics. The efforts to develop an efficacious candidate compound will evolve through three specific aims. In the first Aim, we will complete an initial analog series and select two lead compounds to move forward into animal studies in the second specific aim. These studies will determine key pharmacokinetic parameters (bioavailability, half-life) for our compounds as well as determine efficacy in an animal model of infection. In the third specific aim, we will explore new, structure-based designs to enhance the selectivity of our compounds for the pathogenic forms of DHFR over the human homolog. Completion of these studies will position us to attract outside investors and partners to progress our compounds for an IND application. PUBLIC HEALTH RELEVANCE: Despite decades of work on the discovery of antibiotics, the continued emergence of resistance organisms threatens to render many of our best antibiotics obsolete. We are working to develop new agents against that function as effective monotherapies against the methicillin-resistant strain of Staphylococcus aureus (MRSA) and Streptococcus pyogenes. Specifically we are targeting the essential enzyme dihydrofolate reductase (DHFR) that is required by the bacteria to synthesize key components needed to replicate its genetic material.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government